[go: up one dir, main page]

MX2019011196A - Neurotoxinas botulinas para uso en terapia. - Google Patents

Neurotoxinas botulinas para uso en terapia.

Info

Publication number
MX2019011196A
MX2019011196A MX2019011196A MX2019011196A MX2019011196A MX 2019011196 A MX2019011196 A MX 2019011196A MX 2019011196 A MX2019011196 A MX 2019011196A MX 2019011196 A MX2019011196 A MX 2019011196A MX 2019011196 A MX2019011196 A MX 2019011196A
Authority
MX
Mexico
Prior art keywords
botulin
neurotoxins
therapy
compositions
methods
Prior art date
Application number
MX2019011196A
Other languages
English (en)
Other versions
MX394918B (es
Inventor
Abushakra Sawsan
Ahmad Wajdie
Hasan Fauad
Jarpe Michael
Original Assignee
Bonti Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonti Inc filed Critical Bonti Inc
Publication of MX2019011196A publication Critical patent/MX2019011196A/es
Publication of MX394918B publication Critical patent/MX394918B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

En la presente se describen composiciones y métodos para usarse en procedimientos terapéuticos .
MX2019011196A 2017-03-22 2018-03-22 Neurotoxinas botulinas para uso en terapia MX394918B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762474744P 2017-03-22 2017-03-22
US201762474749P 2017-03-22 2017-03-22
US201762508215P 2017-05-18 2017-05-18
PCT/US2018/023709 WO2018175688A1 (en) 2017-03-22 2018-03-22 Botulinum neurotoxins for use in therapy

Publications (2)

Publication Number Publication Date
MX2019011196A true MX2019011196A (es) 2020-01-20
MX394918B MX394918B (es) 2025-03-24

Family

ID=63584698

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019011196A MX394918B (es) 2017-03-22 2018-03-22 Neurotoxinas botulinas para uso en terapia
MX2022010186A MX2022010186A (es) 2017-03-22 2019-09-20 Neurotoxinas botulinas para uso en terapia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010186A MX2022010186A (es) 2017-03-22 2019-09-20 Neurotoxinas botulinas para uso en terapia.

Country Status (11)

Country Link
US (2) US11260114B2 (es)
EP (1) EP3600221A4 (es)
JP (2) JP7604222B2 (es)
KR (1) KR20190126894A (es)
CN (1) CN110691579A (es)
AU (3) AU2018237198B2 (es)
BR (1) BR112019019743B1 (es)
CA (1) CA3057302A1 (es)
MX (2) MX394918B (es)
RU (2) RU2022102750A (es)
WO (1) WO2018175688A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7604222B2 (ja) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
WO2018195474A1 (en) * 2017-04-21 2018-10-25 Bonti, Inc. Initiating neurotoxin treatments
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US11957740B2 (en) 2021-03-13 2024-04-16 Prime Bio, Inc. Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency
GB202206362D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2123837C1 (ru) * 1998-05-27 1998-12-27 Бритун Юлия Анатольевна Способ устранения морщин
AU1706400A (en) * 1998-10-27 2000-05-15 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
EP1799254A1 (en) 2004-09-27 2007-06-27 Merz Pharma GmbH & Co.KGaA Clostridial neurotoxins for use in tissue healing
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
WO2007044809A2 (en) 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
US8361055B2 (en) * 2008-11-25 2013-01-29 Tucker Peter L Syringe and method for reconstitution of dry-form drugs and medicines
BRPI0923731B1 (pt) * 2008-12-31 2024-02-06 Revance Therapeutics, Inc Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
WO2011022357A2 (en) * 2009-08-17 2011-02-24 East Carolina University Fast acting snare-cleaving enzymes
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US9050337B2 (en) * 2011-06-27 2015-06-09 Sang Duck Kim Method for treating atrophic skin scars using a mixture of botulinum toxin and air
RU2646110C2 (ru) * 2011-11-09 2018-03-01 Мерц Фарма Гмбх Унд Ко. Кгаа Нейротоксины, проявляющие укороченную биологическую активность
US10076558B2 (en) * 2014-02-18 2018-09-18 Rnw Skn, Llc Prophylactic normalization of cutaneous wound repair
WO2015153377A1 (en) * 2014-04-03 2015-10-08 Enhance Skin Products, Inc. Methods and compositions for enhancing and extending the cosmetic effects of non-surgical dermal interventions
JP6601922B2 (ja) * 2015-01-09 2019-11-06 イプセン バイオイノベーション リミテッド 陽イオン性神経毒
KR102794108B1 (ko) * 2015-10-29 2025-04-11 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법
SG11201810975UA (en) * 2016-06-10 2019-01-30 Lonza Ag Method for stabilizing proteins
WO2018106339A1 (en) * 2016-12-06 2018-06-14 Bonti, Inc. Botulinum neurotoxins for use in tendon repair surgery
JP7604222B2 (ja) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
AU2018237205A1 (en) * 2017-03-22 2019-10-31 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2018195474A1 (en) * 2017-04-21 2018-10-25 Bonti, Inc. Initiating neurotoxin treatments
US20210108187A1 (en) * 2017-04-28 2021-04-15 Bonti, Inc. Botulinum neurotoxins production methods
EP3642222A1 (en) * 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
US20210145955A1 (en) * 2017-06-26 2021-05-20 Bonti, Inc. Clostridial neurotoxin formulations and use
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring
JP2021520373A (ja) * 2018-04-03 2021-08-19 ボンチ インコーポレイテッド Ｃｇｒｐを阻害する際に使用するための神経毒素
US10464178B1 (en) * 2018-10-11 2019-11-05 Samuel J. Steeb Method and assembly for docking and retrieving a filament holding device
WO2021041978A1 (en) * 2019-08-30 2021-03-04 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache

Also Published As

Publication number Publication date
KR20190126894A (ko) 2019-11-12
JP2020511548A (ja) 2020-04-16
RU2019132648A3 (es) 2021-06-23
CN110691579A (zh) 2020-01-14
US20200046814A1 (en) 2020-02-13
US11260114B2 (en) 2022-03-01
RU2019132648A (ru) 2021-04-22
AU2018237198A1 (en) 2019-10-31
RU2766147C2 (ru) 2022-02-08
RU2022102750A (ru) 2022-03-28
BR112019019743B1 (pt) 2022-12-13
JP2023076463A (ja) 2023-06-01
JP7604222B2 (ja) 2024-12-23
EP3600221A4 (en) 2021-01-13
MX2022010186A (es) 2022-09-19
BR112019019743A2 (pt) 2020-04-14
CA3057302A1 (en) 2018-09-27
US20230027850A1 (en) 2023-01-26
AU2022215253A1 (en) 2022-09-01
AU2018237198B2 (en) 2022-09-01
WO2018175688A1 (en) 2018-09-27
MX394918B (es) 2025-03-24
EP3600221A1 (en) 2020-02-05
AU2025200598A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
MX2019011196A (es) Neurotoxinas botulinas para uso en terapia.
DOP2020000021A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
BR112019012338A2 (pt) liberação de proteína à base de bactérias de virulência atenuada
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
MX394865B (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
AR089993A1 (es) Macrociclos peptidomimeticos
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
MX2017005325A (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017005666A2 (pt) micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
HUE058151T2 (hu) Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra